Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
July 18, 2024
PDF Version
-- Continued Improvements in RSBQ and CGI-I scores seen with long-term DAYBUE treatment in Phase 3 LAVENDER™ and LILAC studies
-- DAYBUE safety profile was consistent with findings from the LAVENDER trial
Acadia, page-676
-
- There are more pages in this discussion • 141 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.53 |
Change
-0.030(0.19%) |
Mkt cap ! $1.988B | |||
| Open | High | Low | Value | Volume |
| $15.61 | $15.93 | $15.45 | $874.1K | 56.11K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 438 | $15.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.53 | 75 | 4 |
View Market Depth
| Last trade - 10.41am 20/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |